2. Public Health Agency of Canada. Notifiable Disease Charts. https://diseases.canada.ca/notifiable/charts-list

3. Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Reports. https://www.cdc.gov/meningococcal/surveillance/ index.html#enhanced-reports

4. New Zealand Ministry of Health. Meningococcal Disease Reports. https://surv.esr.cri.nz/surveillance/Meningococcal_disease

5. Thompson M.J., Ninis N., Perera R., Mayon-White R., Phillips C., Bailey L. et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367: 397–403. DOI: 10.1016/S0140-6736(06)67932-4

6. Beebeejaun K., Parikh S.R., Campbell H., Gray S., Borrow R., Ramsay M.E. et al. Invasive meningococcal disease: Timing and cause of death in England, 2008–2015. J. Infect. 2020; 80(3): 286–90. DOI: 10.1016/j.jinf.2019.12.008

7. Wang B., Santoreneos R., Giles L., Afzali H.H.A., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine 2019; 37(21): 2768–82. DOI: 10.1016/ j.vaccine.2019.04.020

8. Deghmane A.E., Taha S., Taha M.K. Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review. Infect. Dis. (Lond.) 2022; 54(1): 1–7. DOI: 10.1080/23744235.2021.1971289

9. Olbrich K.J., Müller D., Schumacher S., Beck E., Koerber E. Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers. Infect. Dis. Ther. 2018; 7: 421–38. DOI: 10.1007/s40121-018-0213-2

10. Koomen I., Raat H., Jennekens-Schinkel A., Grobbee D.E., Roord J.J., Roord J.J. et al. Academic and behavioral limitations and health-related quality of life in school age survivors of bacterial meningitis. Qual. Life Res. 2005; 14(6): 1563–72. DOI: 10.1007/s11136-004-7706-z

11. Christensen H., May M., Bowen L., Hickman V., Trotter C.L Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; 10(12): 853–61. DOI: 10.1016/S1473-3099(10)70251-6

12. Wright C., Wordsworth R., Glennie L. Counting the Cost of Meningococcal Disease Scenarios of Severe Meningitis and Septicemia. Pediatr. Drugs. Paediatr Drugs. 2013;15(1): 49–58. DOI: 10.1007/s40272-012-0006-0

13. Darbà J., Kaskens L., Hark M., Wright C. Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine 2014; 32: 5006–12. DOI: 10.1016/j.vaccine.2014.07.019

14. World Health Organization. Defeating meningitis by 2030: a global road map. https://iris.who.int/bitstream/handle/10665/342010/9789240026407eng.pdf? sequence=1

15. Лабораторная диагностика менингококковой инфекции и гнойных бактериальных менингитов: Методические указания МУК 4.2.1887-04. М., 2005.

[Laboratory diagnosis of meningococcal infection and purulent bacterial meningitis: Methodological guidelines of MUC 4.2.1887-04]. Moscow, 2005. (In Russ.).

16. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol. Rec. 2011; 86(47): 521–39. who-position-paper-on-meningococca-vaccine.pdf

17. Лыткина И.Н., Чистякова Г.Г., Королева И.С. Профилактика бактериальных гнойных менингитов у детей в Москве. Новости вакцинопрофилактики. Вакцинация. Информационный бюллетень 1999; (2): 1–11.

Lytkina I.N., Chistyakova G.G., Koroleva I.S.

18. Booy R., Gentile A., Nissen M., Whelan J., Abitbo V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum. Vaccin Immunother. 2019; 15(2): 470–80. DOI: 10.1080/21645515. 2018.1532248

19. Potts C.C., Retchless A.C., McNamara L.A., Marasini D., Reese N., Swint S. et al. Acquisition of ciprofloxacin resistance among an expanding clade of β-lactamase– positive, serogroup Y Neisseria meningitidis in the United States. Clin. Infect. Dis. 2021; 73(7): 1185–93. DOI: 10.1093/cid/ ciab358

20. Ladhani S.N., Lucidarme J., Parikh S.R., Campbell Н., Borrow R., Ramsay M.E. et al. Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis. Lancet 2020; 395(10240): 1865–77. DOI: 10.1016/S0140-6736(20)30913-2

21. Костюкова Н.Н., Бехало В.А., Чернышова Т.Ф. Менингококковая инфекция в Российской Федерации: прошлое и ближайшие перспективы. Эпидемиол. инфекц. болезни. Актуал. вопр. 2014; (2): 73–9.

Kostyukova N.N., Behal/o V.A., Chernyshova T.F.